Form 4: Dynavax Director Lauren Silvernail Receives Equity Compensation Grant

Dynavax Technologies Corp. Director Lauren P. Silvernail has acquired 1,439 restricted stock units and 7,125 stock options as part of a compensation grant, as reported in a recent SEC Form 4 filing.

Summary

• Lauren P. Silvernail, a Director of Dynavax Technologies Corp. (DVAX), acquired 1,439 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 11, 2025.
• These RSUs were granted at a price of $0 and represent a contingent right to receive one share of DVAX Common Stock per RSU.
• The RSUs will fully vest one year from the grant date, provided Ms. Silvernail continues to provide services to the company through such vesting date.
• The release of RSU shares shall be mandatorily deferred six months and one day after Ms. Silvernail no longer provides services to the company.
• Additionally, Ms. Silvernail acquired 7,125 stock options on June 11, 2025, with an exercise price of $10.18 per share.
• These stock options were granted at a price of $0 and will fully vest and become exercisable one year from the grant date, contingent on her continued service to the company.
• The stock options have an expiration date of June 10, 2032.
• Following these transactions, Ms. Silvernail beneficially owns 10,075 shares of Common Stock directly and 7,125 stock options directly.

Sentiment

Score: 6

Explanation: The filing reports a routine equity compensation grant to a director, which is a neutral to slightly positive event as it aligns director interests with shareholders. It does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The grant of restricted stock units and stock options to a director aligns the director's interests with long-term shareholder value.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The filing indicates future vesting events for the granted restricted stock units and stock options, contingent on the director's continued service to the company through June 11, 2026. The stock options have an expiration date of June 10, 2032, providing a long-term incentive.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a director, a common practice across various industries, including the biotechnology sector where Dynavax Technologies Corp. operates. Such grants are standard mechanisms to align executive and director incentives with long-term company performance and shareholder interests.

Comparison to Industry Standards

• Equity grants to directors, including Restricted Stock Units (RSUs) and stock options, are a standard component of compensation packages in publicly traded companies, particularly within the biotechnology and pharmaceutical sectors.
• The vesting schedule of one year for these grants is typical for director compensation, aiming to retain talent and align interests over a reasonable period.
• The exercise price of $10.18 for the options would be compared to the market price of DVAX stock on the grant date to assess if they were granted at-the-money, in-the-money, or out-of-the-money, which is a common practice. Specific comparable companies or projects are not detailed in this filing, as it focuses solely on an individual's transaction.

Related Party Transactions

• The acquisition of Restricted Stock Units and stock options by Lauren P. Silvernail, a Director of Dynavax Technologies Corp., represents a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially encouraging decisions that enhance long-term stock value.

Next Steps

• The 1,439 Restricted Stock Units are expected to fully vest one year from the grant date (June 11, 2026), contingent on continued service.
• The 7,125 Stock Options are expected to fully vest and become exercisable one year from the grant date (June 11, 2026), contingent on continued service.
• The release of RSU shares will be mandatorily deferred six months and one day after the reporting person no longer provides services to the company.
• The stock options will expire on June 10, 2032.

Key Dates

Recommendation

Keywords

Dynavax Technologies Corp, DVAX, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Equity Grant, Lauren P Silvernail